After Negative FDA Committee Vote, Jazz Has Few Notes To Play Beyond Fibromyalgia
This article was originally published in The Pink Sheet Daily
Executive Summary
Jazz's reformulation of sodium oxybate for fibromyalgia ran into advisory committee skepticism last week, but at least one analyst predicts FDA will override the 20-2 negative vote.
You may also be interested in...
Freed From Pfizer, Capsugel May Find More Market Opportunities
Pfizer's divestiture of Capsugel moves the gelatin capsule manufacturer out from under pharma ownership, potentially opening a door to more business.
Freed From Pfizer, Capsugel May Find More Market Opportunities
Pfizer's divestiture of Capsugel moves the gelatin capsule manufacturer out from under pharma ownership, potentially opening a door to more business.
Freed From Pfizer, Capsugel May Find More Market Opportunities
Deal heightens attention Pfizer is attracting from the investment community, already anticipating divestments outside the firm's innovative core pharma business.